ZA200206219B - Dibenzo (B.F.) azepine intermediates. - Google Patents
Dibenzo (B.F.) azepine intermediates. Download PDFInfo
- Publication number
- ZA200206219B ZA200206219B ZA200206219A ZA200206219A ZA200206219B ZA 200206219 B ZA200206219 B ZA 200206219B ZA 200206219 A ZA200206219 A ZA 200206219A ZA 200206219 A ZA200206219 A ZA 200206219A ZA 200206219 B ZA200206219 B ZA 200206219B
- Authority
- ZA
- South Africa
- Prior art keywords
- formula
- compound
- dibenzo
- solution
- added
- Prior art date
Links
- UZVGSSNIUNSOFA-UHFFFAOYSA-N dibenzofuran-1-carboxylic acid Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2C(=O)O UZVGSSNIUNSOFA-UHFFFAOYSA-N 0.000 title description 3
- 239000000543 intermediate Substances 0.000 title description 2
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 60
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 15
- 238000006243 chemical reaction Methods 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 230000021235 carbamoylation Effects 0.000 claims description 7
- 229910052751 metal Inorganic materials 0.000 claims description 7
- 239000002184 metal Substances 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 claims description 6
- 238000006798 ring closing metathesis reaction Methods 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 239000000725 suspension Substances 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- 239000012071 phase Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 4
- GOSNMUNJYZVVFQ-UHFFFAOYSA-N 2-[2-(n-methoxycarbonylanilino)phenyl]acetic acid Chemical compound C=1C=CC=C(CC(O)=O)C=1N(C(=O)OC)C1=CC=CC=C1 GOSNMUNJYZVVFQ-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229940093499 ethyl acetate Drugs 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- CJDWRGVEXAAQRB-UHFFFAOYSA-N methyl n-[2-(dimethylcarbamoyl)phenyl]-n-(2-methylphenyl)carbamate Chemical compound C=1C=CC=C(C(=O)N(C)C)C=1N(C(=O)OC)C1=CC=CC=C1C CJDWRGVEXAAQRB-UHFFFAOYSA-N 0.000 description 2
- 229960001816 oxcarbazepine Drugs 0.000 description 2
- 229920000137 polyphosphoric acid Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- OWPNVXATCSXTBK-UHFFFAOYSA-N 1-phenyl-3h-indol-2-one Chemical compound O=C1CC2=CC=CC=C2N1C1=CC=CC=C1 OWPNVXATCSXTBK-UHFFFAOYSA-N 0.000 description 1
- -1 1.1 eq.) Substances 0.000 description 1
- ZFXVFMBOFIEPII-UHFFFAOYSA-N 1h-azepine-4-carboxamide Chemical compound NC(=O)C1=CC=CNC=C1 ZFXVFMBOFIEPII-UHFFFAOYSA-N 0.000 description 1
- WAEMHISTVIYWOY-UHFFFAOYSA-N 2-(2-methylanilino)benzoic acid Chemical compound CC1=CC=CC=C1NC1=CC=CC=C1C(O)=O WAEMHISTVIYWOY-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 150000001913 cyanates Chemical class 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- KUNLJAIXGWRPFX-UHFFFAOYSA-N methyl 5-methoxybenzo[b][1]benzazepine-11-carboxylate Chemical compound C1=C(OC)C2=CC=CC=C2N(C(=O)OC)C2=CC=CC=C21 KUNLJAIXGWRPFX-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- TUXIEEHOZUFLSY-UHFFFAOYSA-N n,n-dimethyl-2-(2-methylanilino)benzamide Chemical compound CN(C)C(=O)C1=CC=CC=C1NC1=CC=CC=C1C TUXIEEHOZUFLSY-UHFFFAOYSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- GKKCIDNWFBPDBW-UHFFFAOYSA-M potassium cyanate Chemical compound [K]OC#N GKKCIDNWFBPDBW-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- ZVCDLGYNFYZZOK-UHFFFAOYSA-M sodium cyanate Chemical compound [Na]OC#N ZVCDLGYNFYZZOK-UHFFFAOYSA-M 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- 229940061414 trileptal Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
- C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
- C07D223/24—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
- C07D223/26—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom having a double bond between positions 10 and 11
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
- C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
- C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
- C07D223/24—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
- C07D223/28—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom having a single bond between positions 10 and 11
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Epoxy Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0002740.9A GB0002740D0 (en) | 2000-02-07 | 2000-02-07 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200206219B true ZA200206219B (en) | 2003-04-04 |
Family
ID=9885081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200206219A ZA200206219B (en) | 2000-02-07 | 2002-08-05 | Dibenzo (B.F.) azepine intermediates. |
Country Status (34)
Country | Link |
---|---|
US (1) | US7112673B2 (el) |
EP (2) | EP2067772B1 (el) |
JP (1) | JP4859322B2 (el) |
KR (5) | KR101216285B1 (el) |
CN (2) | CN100455572C (el) |
AR (2) | AR029442A1 (el) |
AT (2) | ATE427938T1 (el) |
AU (1) | AU767724B2 (el) |
BR (1) | BR0107922A (el) |
CA (3) | CA2639210C (el) |
CO (1) | CO5271705A1 (el) |
CY (1) | CY1111567T1 (el) |
CZ (1) | CZ301572B6 (el) |
DE (2) | DE60138271D1 (el) |
DK (1) | DK2067772T3 (el) |
ES (2) | ES2363490T3 (el) |
GB (1) | GB0002740D0 (el) |
HK (1) | HK1052501A1 (el) |
HU (1) | HU229420B1 (el) |
IL (3) | IL150613A0 (el) |
MX (1) | MXPA02007629A (el) |
MY (1) | MY136474A (el) |
NO (1) | NO324949B1 (el) |
NZ (1) | NZ520329A (el) |
PE (1) | PE20011078A1 (el) |
PL (2) | PL217225B1 (el) |
PT (2) | PT2067772E (el) |
RU (1) | RU2303591C2 (el) |
SI (1) | SI2067772T1 (el) |
SK (1) | SK287217B6 (el) |
TR (1) | TR200201655T2 (el) |
TW (1) | TWI284638B (el) |
WO (1) | WO2001056992A2 (el) |
ZA (1) | ZA200206219B (el) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1302464A1 (en) * | 2001-10-09 | 2003-04-16 | Max India Limited | Process for preparation of 10-methoxycarbamazepine |
US6670472B2 (en) | 2001-10-09 | 2003-12-30 | Max India Limited | Process for the preparation of 10-methoxycarbamazepine |
CA2486560A1 (en) * | 2002-06-14 | 2003-12-24 | Taro Pharmaceuticals U.S.A., Inc. | Method of preparing a 5h-dibenz[b,f]azepine-5-carboxamide |
ITMI20040452A1 (it) | 2004-03-09 | 2004-06-09 | Clariant Lsm Italia Spa | Processo per la preparazione di oxcarbazepina |
RS53599B1 (en) | 2005-05-10 | 2015-02-27 | Intermune, Inc. | PIRIDON DERIVATIVES FOR STRESS MODULATION OF ACTIVATED PROTEIN KINASE SYSTEMS |
MX2008013675A (es) * | 2006-04-26 | 2009-03-06 | Supernus Pharmaceuticals Inc | Preparaciones de liberacion controlada de oxcarbacepina que tienen perfil de liberacion sigmoidal. |
US20090082335A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched oxcarbazepine |
CA2726588C (en) | 2008-06-03 | 2019-04-16 | Karl Kossen | Compounds and methods for treating inflammatory and fibrotic disorders |
WO2014049550A1 (en) | 2012-09-26 | 2014-04-03 | Ranbaxy Laboratories Limited | Process for the preparation of oxcarbazepine and its use as intermediate in the preparation of eslicarbazepine acetate |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
AU2014318748B2 (en) * | 2013-09-11 | 2019-02-28 | Duquesne University Of The Holy Ghost | Novel anthranilic amides and the use thereof |
KR102373700B1 (ko) | 2014-04-02 | 2022-03-11 | 인터뮨, 인크. | 항섬유성 피리디논 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4847374A (en) * | 1987-01-27 | 1989-07-11 | Ciba-Geigy Corporation | Process for the manufacture of N,N-(Dibenzohexatrienylene)ureas |
IT1272897B (it) * | 1995-01-13 | 1997-07-01 | I F C Iniziative Finanziaarie | Processo per la produzione di 10-oxo-10,11-diidro-sh- -dibenz(b,f) azepin-5-carbossiammide |
US6355680B1 (en) * | 1996-02-20 | 2002-03-12 | Exocell, Inc. | Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies |
IT1283594B1 (it) * | 1996-04-12 | 1998-04-22 | Trifarma Srl | Derivati della 5h-dibenz- (b,f)-azepin-5-carbossiammide, loro preparazione e uso come sostanze ad azione medicinale |
ATE344791T1 (de) * | 1997-07-01 | 2006-11-15 | Warner Lambert Co | 2-(4-brom or 4-iod phenylamino)benzoesäurederivate und ihre anwendung als mek-inhibitoren |
US6048856A (en) * | 1997-12-17 | 2000-04-11 | Novo Nordisk A/S | Heterocyclic compounds |
-
2000
- 2000-02-07 GB GBGB0002740.9A patent/GB0002740D0/en not_active Ceased
-
2001
- 2001-02-05 AR ARP010100515A patent/AR029442A1/es not_active Application Discontinuation
- 2001-02-05 PE PE2001000121A patent/PE20011078A1/es not_active Application Discontinuation
- 2001-02-06 CO CO01008602A patent/CO5271705A1/es active IP Right Grant
- 2001-02-06 MY MYPI20010513A patent/MY136474A/en unknown
- 2001-02-07 PT PT09153375T patent/PT2067772E/pt unknown
- 2001-02-07 KR KR1020107000738A patent/KR101216285B1/ko not_active IP Right Cessation
- 2001-02-07 DK DK09153375.2T patent/DK2067772T3/da active
- 2001-02-07 BR BR0107922-0A patent/BR0107922A/pt not_active Application Discontinuation
- 2001-02-07 PL PL392476A patent/PL217225B1/pl unknown
- 2001-02-07 EP EP09153375A patent/EP2067772B1/en not_active Expired - Lifetime
- 2001-02-07 CZ CZ20022676A patent/CZ301572B6/cs not_active IP Right Cessation
- 2001-02-07 CA CA2639210A patent/CA2639210C/en not_active Expired - Fee Related
- 2001-02-07 RU RU2002123334/04A patent/RU2303591C2/ru not_active IP Right Cessation
- 2001-02-07 EP EP01915203A patent/EP1265868B1/en not_active Expired - Lifetime
- 2001-02-07 ES ES09153375T patent/ES2363490T3/es not_active Expired - Lifetime
- 2001-02-07 KR KR1020027010123A patent/KR20020071033A/ko not_active Application Discontinuation
- 2001-02-07 AT AT01915203T patent/ATE427938T1/de active
- 2001-02-07 US US10/182,980 patent/US7112673B2/en not_active Expired - Lifetime
- 2001-02-07 PL PL356404A patent/PL214039B1/pl unknown
- 2001-02-07 PT PT01915203T patent/PT1265868E/pt unknown
- 2001-02-07 KR KR1020087027467A patent/KR20080103608A/ko not_active Application Discontinuation
- 2001-02-07 KR KR1020097019039A patent/KR100966209B1/ko active IP Right Grant
- 2001-02-07 JP JP2001556842A patent/JP4859322B2/ja not_active Expired - Lifetime
- 2001-02-07 ES ES01915203T patent/ES2324900T3/es not_active Expired - Lifetime
- 2001-02-07 IL IL15061301A patent/IL150613A0/xx unknown
- 2001-02-07 HU HU0300243A patent/HU229420B1/hu unknown
- 2001-02-07 KR KR1020077029687A patent/KR100931753B1/ko not_active IP Right Cessation
- 2001-02-07 SI SI200130996T patent/SI2067772T1/sl unknown
- 2001-02-07 DE DE60138271T patent/DE60138271D1/de not_active Expired - Lifetime
- 2001-02-07 CA CA2724295A patent/CA2724295C/en not_active Expired - Fee Related
- 2001-02-07 CN CNB2005100853024A patent/CN100455572C/zh not_active Expired - Lifetime
- 2001-02-07 DE DE60144456T patent/DE60144456D1/de not_active Expired - Lifetime
- 2001-02-07 AU AU42373/01A patent/AU767724B2/en not_active Ceased
- 2001-02-07 TR TR2002/01655T patent/TR200201655T2/xx unknown
- 2001-02-07 AT AT09153375T patent/ATE505459T1/de active
- 2001-02-07 NZ NZ520329A patent/NZ520329A/en not_active IP Right Cessation
- 2001-02-07 CA CA002395601A patent/CA2395601C/en not_active Expired - Fee Related
- 2001-02-07 WO PCT/EP2001/001330 patent/WO2001056992A2/en active Application Filing
- 2001-02-07 MX MXPA02007629A patent/MXPA02007629A/es active IP Right Grant
- 2001-02-07 SK SK1126-2002A patent/SK287217B6/sk not_active IP Right Cessation
- 2001-02-07 CN CNB018035302A patent/CN1244563C/zh not_active Expired - Lifetime
- 2001-02-09 TW TW090102908A patent/TWI284638B/zh not_active IP Right Cessation
-
2002
- 2002-07-04 IL IL150613A patent/IL150613A/en not_active IP Right Cessation
- 2002-07-26 NO NO20023575A patent/NO324949B1/no not_active IP Right Cessation
- 2002-08-05 ZA ZA200206219A patent/ZA200206219B/en unknown
-
2003
- 2003-05-13 HK HK03103369.4A patent/HK1052501A1/xx not_active IP Right Cessation
-
2007
- 2007-12-17 IL IL188183A patent/IL188183A/en not_active IP Right Cessation
-
2010
- 2010-12-01 AR ARP100104442A patent/AR079237A2/es unknown
-
2011
- 2011-06-16 CY CY20111100572T patent/CY1111567T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL188183A (en) | Intermediates of Dibenzo (F, B) Azpine | |
WO2010112704A1 (fr) | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable | |
CA2455526C (en) | Kinetic resolution of a intermediate useful in the production of benazepril and analogues thereof | |
EP1758867A1 (en) | Process for preparing oxcarbazepine | |
US3992445A (en) | 5-Formamidomethyl-5H-dibenzo[a,d]cycloheptene derivatives | |
RU2007395C1 (ru) | Способ получения 5н-дибенз [b,f]азепинов | |
HU219707B (hu) | 2-es Helyzetben szubsztituált 2-imidazolin-5-on származékok és eljárás az előállításukra | |
EP1181273A1 (en) | New process |